Macitentan

Drug Profile

Macitentan

Alternative Names: ACT-064992; Actelion-1; Opsumit; Zependo

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Actelion Pharmaceuticals; Nippon Shinyaku
  • Class Antifibrotics; Antihypertensives; Antineoplastics; Bromobenzenes; Cardiovascular therapies; Pyrimidines; Skin disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Phase III Eisenmenger complex
  • Phase II Heart failure
  • Clinical Phase Unknown Portal hypertension
  • Discontinued Glioblastoma; Idiopathic pulmonary fibrosis; Skin ulcer

Most Recent Events

  • 10 Apr 2017 Phase-II clinical trials in Heart failure in Austria (PO) (EudraCT2016-003653-15)
  • 10 Apr 2017 Phase-II clinical trials in Heart failure in Hungary (PO) (EudraCT2016-003653-15)
  • 10 Apr 2017 Phase-II clinical trials in Heart failure in Spain (PO) (EudraCT2016-003653-15)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top